Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803247 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL724545 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL1120169 | 1.00 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094498 | 0.89 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094495 | 0.89 | PRKCA (0.32) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7099012 | 0.84 | DAGLA (0.33) | — | |
| SCHEMBL7099016 | 0.84 | DAGLA (0.33) | — | |
| SCHEMBL7095131 | 0.83 | PRKCA (0.30) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7095130 | 0.83 | PRKCA (0.30) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL7094794 | 0.79 | CNR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113330-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113330-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR84 | PRKCA 2125/4885PRKD3 1190/4885PRKCG 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.